Under the agreement, Biowa will receive the right to certain antibody technology from IMUC and selected option rights to IMUC antibodies using the POTELLIGENT Technology.
POTELLIGENT Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyl transferase-knockout CHO cell line as a production cell.
Research shows that POTELLIGENTTechnology enhances ADCC activity of an antibody in vitro, and increases potency and efficacy of the antibody in vivo.
BioWa president and CEO Yasunori Yamaguchi said their decision to partner with IMUC was driven by their interest in novel therapeutic antibody targets in oncology that possess preclinical documentation.